Zituvio, also known by its generic name etrasimod, is a medication used to treat ulcerative colitis [1]. It is an oral medication that works by targeting specific immune cells [2].
What is the mechanism of action for etrasimod (Zituvio)?
Etrasimod is a sphingosine 1-phosphate (S1P) receptor modulator. It selectively binds to S1P receptors 1, 4, and 5, which are found on various immune cells, including lymphocytes. By modulating these receptors, etrasimod reduces the migration of certain types of immune cells from lymph nodes into the central nervous system and other tissues. In the context of ulcerative colitis, this action helps to reduce inflammation in the colon [2].
When did Zituvio (etrasimod) receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved etrasimod (Zituvio) for the treatment of adults with moderately to severely active ulcerative colitis in March 2023 [1].
What is the difference between Zituvio and other ulcerative colitis treatments?
Zituvio is an oral S1P receptor modulator, offering an oral treatment option for ulcerative colitis. Other treatments include biologics, which are often administered by injection or infusion, and other oral medications with different mechanisms of action [2]. This oral administration can be a significant convenience for patients.
What are the potential side effects of Zituvio (etrasimod)?
Common side effects of etrasimod can include upper respiratory tract infections, dizziness, and headache [1]. More serious risks can include bradycardia (slow heart rate), liver enzyme elevations, increased blood pressure, and a rare risk of posterior reversible encephalopathy syndrome (PRES). Patients also have an increased risk of infections while taking this medication [2].
What is the patent status and exclusivity period for Zituvio (etrasimod)?
Information regarding specific patent expiry dates for etrasimod is proprietary and subject to ongoing updates. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can indicate potential market entry for generic or biosimilar versions [3]. Generally, new molecular entities like etrasimod are protected by patents and exclusivity periods that prevent generic competition for a defined duration.
Who manufactures Zituvio (etrasimod)?
Zituvio (etrasimod) is manufactured by Pfizer [1].
Where can I find more information about etrasimod's patents?
DrugPatentWatch.com provides a comprehensive database of drug patent information, including details on etrasimod's patent landscape and potential generic entry timelines [3].
What are the clinical trial results for Zituvio (etrasimod)?
Clinical trials demonstrated that etrasimod was effective in achieving clinical remission and endoscopic improvement in patients with moderately to severely active ulcerative colitis compared to placebo. Studies like the ELEVATE UC trials showed statistically significant improvements in key efficacy endpoints for patients treated with etrasimod [1].
***
Sources:
[1] https://www.drugpatentwatch.com/drug/etrasimod
[2] https://www.drugpatentwatch.com/news/what-is-zituvio-etrasimod
[3] https://www.drugpatentwatch.com